Glenmark Pharmaceuticals Ltd. (India), Galderma (Switzerland), Johnson & Johnson Private Limited (US), GlaxoSmithKline Plc. (UK), and Bausch Health Companies Inc. (Canada) are the leading players in the topical drug delivery market.
The global topical drug delivery market is projected to reach USD 317.8 billion by 2027 from USD 207.4 billion in 2022, at a CAGR of 8.9%. The growth of the topical drug delivery market is mainly driven by factors such as growing prevalence of skin cancer, high demand for drugs that can be self-administered, growing prevalence of chronic diseases which is due to rise in geriatric population, and switching from conventional needle injections to transdermal patches. On the other hand, preference of alternative modes of drug delivery is limiting the market growth to some extent.
To know about the assumptions considered for the study download the pdf brochure
The global topical drug delivery market is consolidated at the top, with various players governing major shares in the market. Some of the major players in the market are Glenmark Pharmaceuticals Ltd. (India), Galderma (Switzerland), Johnson & Johnson Private Limited (US), GlaxoSmithKline Plc. (UK), Bausch Health Companies Inc. (Canada), Hisamitsu Pharmaceuticals Inc. (Japan), Cipla (India), Bayer AG (Germany), Viatris Inc. (Mylan N.V.) (US), and 3M (US).
Glenmark Pharmaceuticals Ltd. (India) has a strong presence in drug discovery, API, and finished dose formulations. The company reorganized itself into three different entities, i.e., Glenmark Pharmaceuticals, Glenmark Life Sciences, and Ichnos Sciences. The company offers branded and generic formulations, over-the-counter products (OTC), active pharmaceutical ingredients (APIs), and novel molecular entities (NMEs) & specialty products. The company has an impressive portfolio of medically vital products in crucial therapy areas such as respiratory, dermatology, and oncology. The company also offers a wide range of topical formulations (such as gels, creams, ointments, and lotions) and generic products through this segment. They offer more than 6,000 products worldwide used in the therapeutic areas of respiratory, dermatology, and oncology. The company has operations in more than 80 countries globally and has offices in 50 countries. In 2020 and 2021, various topical products of the company were approved by the USFDA, which recorded high sales.
Galderma (Switzerland) offers premium brands and services across Aesthetics, Consumer Care, and Prescription Medicine. The company offers topical products under all three segments. Aesthetics consists of hyaluronic acid (HA) fillers and botulinum neuromodulators. Consumer Care brands are Cetaphil, with its wide range of skincare products for all ages; Benzac and Differin OTC for mild-to-moderate acne; and Loceryl, used to treat fungal nail infections. The company operates globally with research and development centers and manufacturing sites throughout the Asia Pacific, Europe, the Middle East, Africa, and North & Latin America. They operate from 50 sites in 40 countries, and more than 1200 employees work at four manufacturing sites. The company is undergoing many product launches and agreements to increase its presence. In February 2022, the company launched Alastin Skincare ReFORM & RePAIR COMPLEX with TriHex Technology. It is designed to assist with recovery from surgical body procedures. It is a unique combination of several Alastin hero technologies, peptides, and various vital ingredients bottled together in one easy-to-use topical formula.
Johnson & Johnson Private Limited (US) primary focus is products related to human health and well-being. J&J operates through three business segments: Consumer Health, Pharmaceutical, and Medical Devices. Topical drug delivery products fall under its Consumer Health and Pharmaceutical business segments. The Consumer Health segment includes a broad range of products focused on personal healthcare used in the Skin health or beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health, and Wound Care. The Pharmaceutical segment is focused on six therapeutic areas: Immunology (e.g., rheumatoid arthritis, inflammatory bowel disease, and psoriasis), Infectious Diseases (e.g., HIV/AIDS), Neuroscience (e.g., mood disorders, neurodegenerative disorders, and schizophrenia), Oncology (e.g., prostate cancer and hematologic malignancies), Cardiovascular and Metabolism (e.g., thrombosis and diabetes), and Pulmonary Hypertension (e.g., Pulmonary Arterial Hypertension). The company has a strong presence across North America, Europe, the Asia Pacific, and Africa. The company completed the acquisition of XBiotech Inc. (US) in 2019. It has an investigational compound, Bermekimab, which is used to treat multiple dermatological diseases, such as atopic dermatitis and hidradenitis suppurativa.
Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) - Global Forecast to 2027
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE